Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS

Autor: Huselton, Eric, Rettig, Michael P., Campbell, Kirsten, Cashen, Amanda F., DiPersio, John F., Gao, Feng, Jacoby, Meagan A., Pusic, Iskra, Romee, Rizwan, Schroeder, Mark A., Uy, Geoffrey L., Marcus, Stephen, Westervelt, Peter *
Zdroj: In Leukemia Research November 2021 110
Databáze: ScienceDirect
Externí odkaz: